STE Maintained at Overweight by Piper Sandler, May 2026

Piper Sandler maintains Overweight rating on STERIS plc (STE), keeping its bullish stance on the medical device company. The Dublin-based infection prevention specialist trades at $219.67, up 1.71% on the day. Stock trades above its 50-day average of $218.28 and below its 200-day average of $242.17. The analyst action reflects confidence in STE’s healthcare market position despite recent sector headwinds.

Piper Sandler Maintains Overweight Rating on STERIS

Piper Sandler kept its Overweight rating on STERIS on May 21, 2026, signaling continued confidence in the company’s growth trajectory. The analyst firm posed the question “Is now the time to buy STERIS?” in its coverage update, suggesting potential entry points for investors. This maintained rating reflects steady conviction in the stock’s ability to outperform the broader market.

The rating action comes as STE trades near its 50-day moving average, indicating technical stability. With a market cap of $21.55 billion and 98.1 million shares outstanding, STERIS remains a significant player in the medical device sector. The stock’s 1.58% single-day gain demonstrates investor interest in the maintained positive outlook.

Financial Metrics and Valuation Analysis

STERIS trades at a P/E ratio of 27.47x, reflecting premium valuation typical for healthcare innovators. The company generates $60.57 in revenue per share and $7.98 in net income per share on a trailing twelve-month basis. Free cash flow per share stands at $9.92, supporting the company’s dividend of $2.46 per share and 1.12% yield.

The company’s debt-to-equity ratio of 0.27x demonstrates conservative leverage, while interest coverage of 18.15x shows strong ability to service obligations. Return on equity reaches 11.05%, indicating efficient capital deployment. Piper Sandler’s analysis highlights STERIS’s competitive positioning within the medical device landscape.

Meyka AI Grade and Analyst Consensus

Meyka AI rates STE with a grade of B+, reflecting strong fundamentals and market positioning. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests a BUY recommendation based on comprehensive analysis.

Broader analyst consensus shows three Buy ratings and one Hold rating, with no Sell recommendations. This 3-to-1 buy-to-hold ratio underscores market optimism. The company’s three-year net income growth of 149% and five-year revenue growth of 54.9% demonstrate consistent execution in expanding its infection prevention and sterilization services.

Healthcare Sector Positioning and Growth Drivers

STERIS operates across four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment leads with sterile processing equipment and services for hospitals. Applied Sterilization Technologies operates 50 contract sterilization facilities serving medical device manufacturers.

The company’s operating margin of 18.56% and gross margin of 44.25% reflect pricing power and operational efficiency. Free cash flow growth of 26.9% year-over-year supports capital investments and shareholder returns. With 18,000 full-time employees globally, STERIS maintains scale advantages in infection prevention solutions critical to healthcare providers worldwide.

Final Thoughts

Piper Sandler’s maintained Overweight rating on STERIS reflects confidence in the company’s market position and growth prospects within healthcare. The stock’s B+ grade from Meyka AI, combined with strong analyst consensus and solid financial metrics, supports the bullish outlook. STERIS’s diversified revenue streams, strong cash generation, and conservative balance sheet position it well for sustained performance in the medical device sector. These grades and ratings are not guaranteed, and we are not financial advisors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.